Abstract 76P
Background
The study is aimed to identify perception and satisfaction of cancer patients who participate in clinical trials.
Methods
The participants of the study were 110 cancer patients who participated in clinical trials over 2nd cycle at a tertiary hospital, Seoul, South Korea. The instruments used were the perception and satisfaction of cancer patients in clinical trials developed after evaluating content validity index. The collected data were analyzed with descriptive statistics, independent t-test, one-way ANOVA and Pearson Correlation Coefficients.
Results
The mean perception of clinical trial of patients was 3.97±0.46 out of 5.0. The mean satisfaction of clinical trial of patients was 4.10±0.55 out of 5.0. The perception of cancer patients in clinical trials was significantly difference according to types of cancers (F = 2.88, p=.018), participation period (F = 3.13, p=.029) and subjective understanding of the clinical trial (t = 2.65, p=.015). Satisfaction of cancer patients showed significant difference according to religion (t = 2.32, p=.023), participation period (F = 3.39, p=.021), motive to participate (F = 3.18, p=.010) and decision maker of participation (t = 2.60, p =.025). Perception and satisfaction of cancer patients in clinical trials were positively correlated (r=.66, p<.001).
Conclusions
The results of study can be used as a basis for education program for cancer patients participating in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract